论文信息 - Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 - 字舞流文

Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

T. Powles | E. Plimack | D. Bajorin | A. Balar | J. Bellmunt | P. O’Donnell | P. Grivas | D. Castellano | N. Hahn | J. Vuky | R. Perini | R. Wit | M. Savage | Lei Pang | S. Keefe